LC3‑Ⅱ/LC3‑Ⅰ Cancer Research Results

LC3‑Ⅱ/LC3‑Ⅰ, ratio of LC3‑Ⅱ/LC3‑Ⅰ: Click to Expand ⟱
Source:
Type: marker
The ratio of LC3-II to LC3-I is often used as a marker for autophagy, a cellular process in which cells recycle their damaged or dysfunctional components. In cancer, autophagy can play a complex role, and the LC3-II/LC3-I ratio can be used to assess autophagic activity.
Many cancers, have an increased LC3-II/LC3-I ratio indicating enhanced autophagy, which can support tumor cell survival, especially under stress conditions (e.g., nutrient deprivation, hypoxia). This is often associated with poor prognosis and treatment resistance.
Cell Survival: Increased autophagy, as indicated by a higher LC3-II/LC3-I ratio, can help cancer cells survive in adverse conditions, contributing to tumor growth and metastasis.
Therapeutic Resistance: Elevated autophagy can lead to resistance against chemotherapy and targeted therapies, as cancer cells may utilize autophagy to survive treatment-induced stress.
Metabolic Adaptation: Autophagy allows cancer cells to adapt to metabolic stress by recycling cellular components, which can support continued proliferation and survival.
Sepsis, Sepsis: Click to Expand ⟱
Sepsis is a potentially life-threatening condition that arises when the body's response to infection causes injury to its own tissues and organs. This initial stage of sepsis is followed by suppression of the immune system. Common signs and symptoms include fever, increased heart rate, increased breathing rate, and confusion.
Scientific Papers found: Click to Expand⟱
7482- H2,    Molecular Hydrogen Therapy: Mechanisms, Delivery Methods, Preventive, and Therapeutic Application
- Review, Var, NA - Review, IBD, NA - Review, Stroke, NA - Review, Sepsis, NA - Review, AD, NA
Dose↝, *Inflam↓, *IL1β↓, *IL6↓, *TNF-α↓, *neuroP↑, *mTOR↓, *IL10↑, *TGF-β↑, *Sepsis↓, *NRF2↑, *antiOx↑, *Catalase↑, *SOD↑, *GPx↑, *ROS↓, *HO-1↑, *PI3K↑, *Akt↑, *hepatoP↑, *MPO↓, *cardioP↑, CDK4↓, CDK6↑, CD47↓, PI3K↓, Akt↓, Hif1a↓, selectivity↑, *MMP↑, *ATP↑, *ER Stress↓, *CHOP/DDIT3↓, *Casp12↓, *GRP78/BiP↓, *p38↓, *p‑JNK↓, *LC3‑Ⅱ/LC3‑Ⅰ↑, *p‑eIF2α↓, *ATF4↓, *XBP-1↓, *Imm↑, *IFN-γ↓, *IL4↓, *GranB/GZMB↓, NK cell↑, radioP↑, *CD4+↑, CD8+↑, *Dose↝, *other↑, *Dose↝, *antiPs↑, *BioAv↝, *GutMicro↑, Dose↝, *IBI↑, TumCP↓, TumCI↓, TumCMig↓, CD8+↑, PGC-1α↑, Akt↓, SCD1↓, *MDA↓, eff↑, *APP↓, *BACE↓, *Aβ↓, *cognitive↑, *neuroP↑, NP/CIPN↓, *Stroke↓, *NLRP3↓, *ALAT↓, *AST↓, *LPS↓, *hepatoP↑, chemoP↑, *creat↓, *Urea↓, *RenoP↑, *eff↑, Apoptosis↑, XIAP↓, IAP2/BIRC3↓, TumVol↓, MALAT1↓, EZH2↓, miR-124-3p↓, eff↑, ChemoSen↑, *compII↑, *compIII↑, *LDL↓, *Obesity↓, QoL↑, PFS↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

CD47↓, 1,   miR-124-3p↓, 1,   PFS↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

PGC-1α↑, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

SCD1↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 2,   Apoptosis↑, 1,   IAP2/BIRC3↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

EZH2↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK4↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

PI3K↓, 1,  

Migration(tgid=13) ⓘ

MALAT1↓, 1,   TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

Hif1a↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

NK cell↑, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

CDK6↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,   Dose↝, 2,   eff↑, 2,   selectivity↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

EZH2↓, 1,  

Functional Outcomes(tgid=23) ⓘ

chemoP↑, 1,   NP/CIPN↓, 1,   QoL↑, 1,   radioP↑, 1,   TumVol↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

CD8+↑, 2,  
Total Targets: 30

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

compII↑, 1,   Stroke↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Catalase↑, 1,   GPx↑, 1,   HO-1↑, 1,   MDA↓, 1,   MPO↓, 1,   NRF2↑, 1,   ROS↓, 1,   SOD↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↑, 1,   compIII↑, 1,   MMP↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,   LDL↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↑, 1,   Casp12↓, 1,   GranB/GZMB↓, 1,   p‑JNK↓, 1,   p38↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↑, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↓, 1,   p‑eIF2α↓, 1,   ER Stress↓, 1,   GRP78/BiP↓, 1,   XBP-1↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

LC3‑Ⅱ/LC3‑Ⅰ↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

mTOR↓, 1,   PI3K↑, 1,  

Migration(tgid=13) ⓘ

APP↓, 1,   TGF-β↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

ATF4↓, 1,  

Barriers & Transport(tgid=15) ⓘ

IBI↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD4+↑, 1,   IFN-γ↓, 1,   IL10↑, 1,   IL1β↓, 1,   IL4↓, 1,   IL6↓, 1,   Imm↑, 1,   Inflam↓, 1,   LPS↓, 1,   TNF-α↓, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,   BACE↓, 1,   NLRP3↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↝, 1,   Dose↝, 2,   eff↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AST↓, 1,   creat↓, 1,   GutMicro↑, 1,   IL6↓, 1,   Urea↓, 1,  

Functional Outcomes(tgid=23) ⓘ

antiPs↑, 1,   cardioP↑, 1,   cognitive↑, 1,   hepatoP↑, 2,   neuroP↑, 2,   Obesity↓, 1,   RenoP↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

Sepsis↓, 1,  
Total Targets: 64

Scientific Paper Hit Count for: LC3‑Ⅱ/LC3‑Ⅰ, ratio of LC3‑Ⅱ/LC3‑Ⅰ
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:65  Cells:%  prod#:%  Target#:685  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page